JP2019162140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019162140A5 JP2019162140A5 JP2019099850A JP2019099850A JP2019162140A5 JP 2019162140 A5 JP2019162140 A5 JP 2019162140A5 JP 2019099850 A JP2019099850 A JP 2019099850A JP 2019099850 A JP2019099850 A JP 2019099850A JP 2019162140 A5 JP2019162140 A5 JP 2019162140A5
- Authority
- JP
- Japan
- Prior art keywords
- region
- class
- crispr
- polynucleotide
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091033409 CRISPR Proteins 0.000 claims 131
- 210000004027 cell Anatomy 0.000 claims 94
- 238000000034 method Methods 0.000 claims 74
- 230000008685 targeting Effects 0.000 claims 49
- 108020004414 DNA Proteins 0.000 claims 47
- 102000053602 DNA Human genes 0.000 claims 47
- 230000000694 effects Effects 0.000 claims 44
- 102000040430 polynucleotide Human genes 0.000 claims 43
- 108091033319 polynucleotide Proteins 0.000 claims 43
- 239000002157 polynucleotide Substances 0.000 claims 43
- 230000004913 activation Effects 0.000 claims 41
- 229920002477 rna polymer Polymers 0.000 claims 41
- 230000003213 activating effect Effects 0.000 claims 35
- 102000039446 nucleic acids Human genes 0.000 claims 35
- 108020004707 nucleic acids Proteins 0.000 claims 35
- 150000007523 nucleic acids Chemical class 0.000 claims 35
- 238000010354 CRISPR gene editing Methods 0.000 claims 23
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims 16
- 108010077850 Nuclear Localization Signals Proteins 0.000 claims 14
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 13
- 229920001184 polypeptide Polymers 0.000 claims 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims 13
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 12
- ANCLJVISBRWUTR-UHFFFAOYSA-N diaminophosphinic acid Chemical compound NP(N)(O)=O ANCLJVISBRWUTR-UHFFFAOYSA-N 0.000 claims 12
- 108090000623 proteins and genes Proteins 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 11
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims 11
- 101710163270 Nuclease Proteins 0.000 claims 10
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 10
- 230000000295 complement effect Effects 0.000 claims 9
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims 8
- 238000000338 in vitro Methods 0.000 claims 8
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims 8
- -1 phosphinates Chemical class 0.000 claims 8
- 108091026890 Coding region Proteins 0.000 claims 7
- 241000251539 Vertebrata <Metazoa> Species 0.000 claims 7
- 230000001580 bacterial effect Effects 0.000 claims 7
- 238000004520 electroporation Methods 0.000 claims 7
- 239000013604 expression vector Substances 0.000 claims 7
- 230000002538 fungal effect Effects 0.000 claims 7
- 210000005260 human cell Anatomy 0.000 claims 7
- 150000002632 lipids Chemical class 0.000 claims 7
- 238000001638 lipofection Methods 0.000 claims 7
- 239000002502 liposome Substances 0.000 claims 7
- 210000004962 mammalian cell Anatomy 0.000 claims 7
- 238000000520 microinjection Methods 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 6
- 102000037865 fusion proteins Human genes 0.000 claims 6
- 230000035897 transcription Effects 0.000 claims 6
- 238000013518 transcription Methods 0.000 claims 6
- 125000004103 aminoalkyl group Chemical group 0.000 claims 5
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 claims 5
- 150000008298 phosphoramidates Chemical class 0.000 claims 5
- 230000001105 regulatory effect Effects 0.000 claims 5
- 108010061100 Nucleoproteins Proteins 0.000 claims 4
- 102000011931 Nucleoproteins Human genes 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 3
- 108010008532 Deoxyribonuclease I Proteins 0.000 claims 2
- 102000007260 Deoxyribonuclease I Human genes 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 230000033616 DNA repair Effects 0.000 claims 1
- 108010046331 Deoxyribodipyrimidine photo-lyase Proteins 0.000 claims 1
- 101000615488 Homo sapiens Methyl-CpG-binding domain protein 2 Proteins 0.000 claims 1
- 102100034343 Integrase Human genes 0.000 claims 1
- 108010061833 Integrases Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 102100021299 Methyl-CpG-binding domain protein 2 Human genes 0.000 claims 1
- 102000016397 Methyltransferase Human genes 0.000 claims 1
- 230000010718 Oxidation Activity Effects 0.000 claims 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 claims 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 claims 1
- 108091000080 Phosphotransferase Proteins 0.000 claims 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims 1
- 108091093078 Pyrimidine dimer Proteins 0.000 claims 1
- 102000018120 Recombinases Human genes 0.000 claims 1
- 108010091086 Recombinases Proteins 0.000 claims 1
- 102000008579 Transposases Human genes 0.000 claims 1
- 108010020764 Transposases Proteins 0.000 claims 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 claims 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 claims 1
- 102000005421 acetyltransferase Human genes 0.000 claims 1
- 108020002494 acetyltransferase Proteins 0.000 claims 1
- 230000002730 additional effect Effects 0.000 claims 1
- 230000006154 adenylylation Effects 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000000254 damaging effect Effects 0.000 claims 1
- 230000009615 deamination Effects 0.000 claims 1
- 238000006481 deamination reaction Methods 0.000 claims 1
- 230000006114 demyristoylation Effects 0.000 claims 1
- 230000027832 depurination Effects 0.000 claims 1
- 230000029180 desumoylation Effects 0.000 claims 1
- 230000009504 deubiquitination Effects 0.000 claims 1
- IVVMYMCCLPZNRL-UHFFFAOYSA-N hydrazinylphosphonic acid Chemical class NNP(O)(O)=O IVVMYMCCLPZNRL-UHFFFAOYSA-N 0.000 claims 1
- 230000007498 myristoylation Effects 0.000 claims 1
- 150000008299 phosphorodiamidates Chemical class 0.000 claims 1
- 102000020233 phosphotransferase Human genes 0.000 claims 1
- 239000013635 pyrimidine dimer Substances 0.000 claims 1
- 230000010741 sumoylation Effects 0.000 claims 1
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562108931P | 2015-01-28 | 2015-01-28 | |
| US62/108,931 | 2015-01-28 | ||
| US201562251548P | 2015-11-05 | 2015-11-05 | |
| US62/251,548 | 2015-11-05 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539643A Division JP6835726B2 (ja) | 2015-01-28 | 2016-01-27 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019162140A JP2019162140A (ja) | 2019-09-26 |
| JP2019162140A5 true JP2019162140A5 (enExample) | 2020-04-16 |
| JP7038079B2 JP7038079B2 (ja) | 2022-03-17 |
Family
ID=55361965
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539643A Active JP6835726B2 (ja) | 2015-01-28 | 2016-01-27 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
| JP2019099850A Active JP7038079B2 (ja) | 2015-01-28 | 2019-05-29 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539643A Active JP6835726B2 (ja) | 2015-01-28 | 2016-01-27 | Ｃｒｉｓｐｒハイブリッドｄｎａ／ｒｎａポリヌクレオチドおよび使用方法 |
Country Status (27)
| Country | Link |
|---|---|
| US (11) | US9650617B2 (enExample) |
| EP (2) | EP4257690A3 (enExample) |
| JP (2) | JP6835726B2 (enExample) |
| KR (4) | KR102319192B1 (enExample) |
| CN (2) | CN111518811A (enExample) |
| AU (3) | AU2016211517B2 (enExample) |
| BR (1) | BR112017016080B1 (enExample) |
| CA (2) | CA2975166C (enExample) |
| DK (1) | DK3250691T5 (enExample) |
| ES (1) | ES2955957T3 (enExample) |
| FI (1) | FI3250691T3 (enExample) |
| GB (1) | GB2550745A (enExample) |
| HR (1) | HRP20231022T1 (enExample) |
| HU (1) | HUE063813T2 (enExample) |
| IL (4) | IL288263B (enExample) |
| LT (1) | LT3250691T (enExample) |
| MX (2) | MX2017009506A (enExample) |
| NZ (1) | NZ733702A (enExample) |
| PL (1) | PL3250691T3 (enExample) |
| PT (1) | PT3250691T (enExample) |
| RS (1) | RS64527B1 (enExample) |
| RU (1) | RU2713328C2 (enExample) |
| SG (3) | SG10201804715WA (enExample) |
| SI (1) | SI3250691T1 (enExample) |
| SM (1) | SMT202300341T1 (enExample) |
| WO (1) | WO2016123230A1 (enExample) |
| ZA (2) | ZA201705174B (enExample) |
Families Citing this family (163)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2689019A2 (en) | 2011-03-23 | 2014-01-29 | Pioneer Hi-Bred International Inc. | Methods for producing a complex transgenic trait locus |
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US10760064B2 (en) | 2013-03-15 | 2020-09-01 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| US10378027B2 (en) | 2013-03-15 | 2019-08-13 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| DK2986729T3 (en) | 2013-04-16 | 2018-10-29 | Regeneron Pharma | TARGETED MODIFICATION OF ROOT THROUGH |
| US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
| CA3221516A1 (en) | 2013-08-22 | 2015-02-26 | E. I. Du Pont De Nemours And Company | Plant genome modification using guide rna/cas endonuclease systems and methods of use |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| WO2015088643A1 (en) | 2013-12-11 | 2015-06-18 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for the targeted modification of a genome |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| WO2016022363A2 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| BR112017003757A2 (pt) | 2014-09-12 | 2017-12-26 | Du Pont | ?plantas de milho, partes de planta de milho ou sementes de milho? |
| AU2015330699B2 (en) | 2014-10-10 | 2021-12-02 | Editas Medicine, Inc. | Compositions and methods for promoting homology directed repair |
| GB201418965D0 (enExample) | 2014-10-24 | 2014-12-10 | Ospedale San Raffaele And Fond Telethon | |
| WO2016073990A2 (en) | 2014-11-07 | 2016-05-12 | Editas Medicine, Inc. | Methods for improving crispr/cas-mediated genome-editing |
| SI3250691T1 (sl) | 2015-01-28 | 2023-10-30 | Caribou Biosciences, Inc. | Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo |
| EP3553178A1 (en) | 2015-03-27 | 2019-10-16 | E. I. du Pont de Nemours and Company | Soybean u6 small nuclear rna gene promoters and their use in constitutive expression of small rna genes in plants |
| GB201506509D0 (en) | 2015-04-16 | 2015-06-03 | Univ Wageningen | Nuclease-mediated genome editing |
| EP3294896A1 (en) | 2015-05-11 | 2018-03-21 | Editas Medicine, Inc. | Optimized crispr/cas9 systems and methods for gene editing in stem cells |
| KR102796744B1 (ko) | 2015-06-09 | 2025-04-15 | 에디타스 메디신, 인코포레이티드 | 이식의 개선을 위한 crispr/cas-관련 방법 및 조성물 |
| US20160362667A1 (en) * | 2015-06-10 | 2016-12-15 | Caribou Biosciences, Inc. | CRISPR-Cas Compositions and Methods |
| US10648020B2 (en) | 2015-06-18 | 2020-05-12 | The Broad Institute, Inc. | CRISPR enzymes and systems |
| US9790490B2 (en) * | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CA2990699A1 (en) | 2015-06-29 | 2017-01-05 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and modified single crispr rna and uses thereof |
| WO2017004279A2 (en) | 2015-06-29 | 2017-01-05 | Massachusetts Institute Of Technology | Compositions comprising nucleic acids and methods of using the same |
| US9512446B1 (en) | 2015-08-28 | 2016-12-06 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| US9926546B2 (en) | 2015-08-28 | 2018-03-27 | The General Hospital Corporation | Engineered CRISPR-Cas9 nucleases |
| EP3353296B1 (en) | 2015-09-24 | 2020-11-04 | Editas Medicine, Inc. | Use of exonucleases to improve crispr/cas-mediated genome editing |
| SG10202104041PA (en) | 2015-10-23 | 2021-06-29 | Harvard College | Nucleobase editors and uses thereof |
| EP3350327B1 (en) | 2015-10-23 | 2018-09-26 | Caribou Biosciences, Inc. | Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids |
| DK3371310T3 (da) * | 2015-12-04 | 2019-08-05 | Caribou Biosciences Inc | Nucleinsyrekonstruerede targetnucleinsyrer |
| CA3007635A1 (en) | 2015-12-07 | 2017-06-15 | Zymergen Inc. | Promoters from corynebacterium glutamicum |
| WO2017100343A1 (en) | 2015-12-07 | 2017-06-15 | Arc Bio, Llc | Methods and compositions for the making and using of guide nucleic acids |
| US9988624B2 (en) | 2015-12-07 | 2018-06-05 | Zymergen Inc. | Microbial strain improvement by a HTP genomic engineering platform |
| US11208649B2 (en) | 2015-12-07 | 2021-12-28 | Zymergen Inc. | HTP genomic engineering platform |
| US11845933B2 (en) | 2016-02-03 | 2023-12-19 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide RNA and its applications |
| US9896696B2 (en) | 2016-02-15 | 2018-02-20 | Benson Hill Biosystems, Inc. | Compositions and methods for modifying genomes |
| US11597924B2 (en) | 2016-03-25 | 2023-03-07 | Editas Medicine, Inc. | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use |
| WO2017180694A1 (en) | 2016-04-13 | 2017-10-19 | Editas Medicine, Inc. | Cas9 fusion molecules gene editing systems, and methods of use thereof |
| SG11201810179RA (en) | 2016-04-19 | 2018-12-28 | Broad Inst Inc | Novel crispr enzymes and systems |
| CN106244591A (zh) * | 2016-08-23 | 2016-12-21 | 苏州吉玛基因股份有限公司 | 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用 |
| EA201892810A1 (ru) | 2016-06-01 | 2019-06-28 | Квс Заат Се | Гибридные последовательности нуклеиновых кислот для геномной инженерии |
| US10767175B2 (en) | 2016-06-08 | 2020-09-08 | Agilent Technologies, Inc. | High specificity genome editing using chemically modified guide RNAs |
| JP2019519242A (ja) | 2016-06-30 | 2019-07-11 | ザイマージェン インコーポレイテッド | 細菌ヘモグロビンライブラリーを生成するための方法およびその使用 |
| WO2018005793A1 (en) | 2016-06-30 | 2018-01-04 | Zymergen Inc. | Methods for generating a glucose permease library and uses thereof |
| WO2018009822A1 (en) | 2016-07-08 | 2018-01-11 | Ohio State Innovation Foundation | Modified nucleic acids, hybrid guide rnas, and uses thereof |
| KR20250103795A (ko) | 2016-08-03 | 2025-07-07 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 아데노신 핵염기 편집제 및 그의 용도 |
| US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
| WO2018031950A1 (en) | 2016-08-12 | 2018-02-15 | Caribou Biosciences, Inc. | Protein engineering methods |
| WO2018034554A1 (ko) | 2016-08-19 | 2018-02-22 | 주식회사 툴젠 | 인위적으로 조작된 신생혈관형성 조절 시스템 |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US11306305B2 (en) | 2016-09-23 | 2022-04-19 | Board Of Trustees Of Southern Illinois University | Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions |
| US11242542B2 (en) | 2016-10-07 | 2022-02-08 | Integrated Dna Technologies, Inc. | S. pyogenes Cas9 mutant genes and polypeptides encoded by same |
| CA3039409A1 (en) | 2016-10-07 | 2018-04-12 | Integrated Dna Technologies, Inc. | S. pyogenes cas9 mutant genes and polypeptides encoded by same |
| SG11201903089RA (en) | 2016-10-14 | 2019-05-30 | Harvard College | Aav delivery of nucleobase editors |
| US20180282722A1 (en) * | 2016-11-21 | 2018-10-04 | Massachusetts Institute Of Technology | Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing |
| AU2017364084B2 (en) * | 2016-11-22 | 2024-07-04 | Integrated Dna Technologies, Inc. | CRISPR/Cpf1 systems and methods |
| US9816093B1 (en) | 2016-12-06 | 2017-11-14 | Caribou Biosciences, Inc. | Engineered nucleic acid-targeting nucleic acids |
| US11293022B2 (en) | 2016-12-12 | 2022-04-05 | Integrated Dna Technologies, Inc. | Genome editing enhancement |
| WO2018119010A1 (en) | 2016-12-19 | 2018-06-28 | Editas Medicine, Inc. | Assessing nuclease cleavage |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| US20190382751A1 (en) * | 2016-12-28 | 2019-12-19 | Ionis Pharmaceuticals, Inc. | Modified crispr rna and uses thereof |
| EP3565907B1 (en) | 2017-01-06 | 2022-05-04 | Editas Medicine, Inc. | Methods of assessing nuclease cleavage |
| DK3574101T5 (da) * | 2017-01-30 | 2024-09-02 | Kws Saat Se & Co Kgaa | Reparationsskabelonbinding til endonukleaser til genommodifikation |
| EP3592381A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Cancer vaccine |
| US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| WO2018165629A1 (en) | 2017-03-10 | 2018-09-13 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
| WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
| PT3526324T (pt) | 2017-03-28 | 2021-10-20 | Locanabio Inc | Proteína associada a crispr (cas) |
| US11499151B2 (en) | 2017-04-28 | 2022-11-15 | Editas Medicine, Inc. | Methods and systems for analyzing guide RNA molecules |
| WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
| US11603544B2 (en) | 2017-06-05 | 2023-03-14 | Fred Hutchinson Cancer Center | Genomic safe harbors for genetic therapies in human stem cells and engineered nanoparticles to provide targeted genetic therapies |
| CN108977442B (zh) * | 2017-06-05 | 2023-01-06 | 广州市锐博生物科技有限公司 | 用于dna编辑的系统及其应用 |
| KR20200026878A (ko) | 2017-06-06 | 2020-03-11 | 지머젠 인코포레이티드 | 균류 균주를 개량하기 위한 htp 게놈 공학 플랫폼 |
| KR20200026874A (ko) | 2017-06-06 | 2020-03-11 | 지머젠 인코포레이티드 | 대장균 개량을 위한 htp 게놈 공학 플랫폼 |
| US20200190508A1 (en) * | 2017-06-07 | 2020-06-18 | Arc Bio, Llc | Creation and use of guide nucleic acids |
| JP7518620B2 (ja) | 2017-06-09 | 2024-07-18 | エディタス・メディシン，インコーポレイテッド | 操作されたｃａｓ９ヌクレアーゼ |
| MX2019015143A (es) | 2017-06-14 | 2020-07-27 | Wisconsin Alumni Res Found | Rna guias modificados, complejos crispr-ribonucleoproteina y metodos de uso. |
| WO2019014564A1 (en) | 2017-07-14 | 2019-01-17 | Editas Medicine, Inc. | SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES |
| US11584955B2 (en) * | 2017-07-14 | 2023-02-21 | Shanghai Tolo Biotechnology Company Limited | Application of Cas protein, method for detecting target nucleic acid molecule and kit |
| CN107488710B (zh) | 2017-07-14 | 2020-09-22 | 上海吐露港生物科技有限公司 | 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒 |
| CN111801345A (zh) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物 |
| CN111373040B (zh) | 2017-08-09 | 2024-07-12 | 本森希尔股份有限公司 | 修饰基因组的组合物和方法 |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| EP3676378A4 (en) | 2017-08-31 | 2021-06-09 | The New York Genome Center | PROCEDURES AND COMPOSITIONS USING CRIMP-CPF1 AND PAIRED GUIDE-CRISPR-RNA FOR PROGRAMMABLE GENOMIC DELETIONS |
| US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
| WO2019099943A1 (en) | 2017-11-16 | 2019-05-23 | Astrazeneca Ab | Compositions and methods for improving the efficacy of cas9-based knock-in strategies |
| US20210002609A1 (en) | 2017-12-05 | 2021-01-07 | Caribou Biosciences, Inc. | Modified lymphocytes |
| WO2019118949A1 (en) | 2017-12-15 | 2019-06-20 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| WO2019118893A1 (en) | 2017-12-15 | 2019-06-20 | Dana-Farber Cancer Institute, Inc. | Stabilized peptide-mediated targeted protein degradation |
| WO2019147743A1 (en) * | 2018-01-26 | 2019-08-01 | Massachusetts Institute Of Technology | Structure-guided chemical modification of guide rna and its applications |
| WO2019152941A1 (en) | 2018-02-05 | 2019-08-08 | Caribou Biosciences, Inc. | Engineered gut microbes for reduction of reactivation of detoxified drugs |
| EP3755792A4 (en) | 2018-02-23 | 2021-12-08 | Pioneer Hi-Bred International, Inc. | NEW CAS9 ORTHOLOGIST |
| WO2019173248A1 (en) | 2018-03-07 | 2019-09-12 | Caribou Biosciences, Inc. | Engineered nucleic acid-targeting nucleic acids |
| GB2587970B (en) | 2018-04-19 | 2023-02-08 | Univ California | Compositions and methods for gene editing |
| EP3794130A4 (en) | 2018-05-16 | 2022-07-27 | Synthego Corporation | METHODS AND SYSTEMS FOR DESIGNING AND USING GUIDE RNA |
| US12157760B2 (en) | 2018-05-23 | 2024-12-03 | The Broad Institute, Inc. | Base editors and uses thereof |
| US12227776B2 (en) | 2018-06-13 | 2025-02-18 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| US10227576B1 (en) | 2018-06-13 | 2019-03-12 | Caribou Biosciences, Inc. | Engineered cascade components and cascade complexes |
| CN112272704A (zh) * | 2018-06-13 | 2021-01-26 | 卡里布生物科学公司 | 改造的cascade组分和cascade复合体 |
| AU2019291918B2 (en) | 2018-06-29 | 2025-06-12 | Editas Medicine, Inc. | Synthetic guide molecules, compositions and methods relating thereto |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| EP3847251A1 (en) | 2018-09-07 | 2021-07-14 | Astrazeneca AB | Compositions and methods for improved nucleases |
| EP3833682B1 (en) | 2018-10-01 | 2022-08-17 | Caribou Biosciences, Inc. | Suicide module compositions and methods |
| KR102126573B1 (ko) | 2018-10-18 | 2020-06-26 | 대한민국 | CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| SG11202104409YA (en) * | 2018-10-31 | 2021-05-28 | Zymergen Inc | Multiplexed deterministic assembly of dna libraries |
| US11739320B2 (en) | 2018-11-05 | 2023-08-29 | Wisconsin Alumni Research Foundation | Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases |
| CN113166744B (zh) | 2018-12-14 | 2025-02-07 | 先锋国际良种公司 | 用于基因组编辑的新颖crispr-cas系统 |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| AU2020210884A1 (en) | 2019-01-25 | 2021-08-12 | Synthego Corporation | Systems and methods for modulating CRISPR activity |
| WO2020176389A1 (en) | 2019-02-25 | 2020-09-03 | Caribou Biosciences, Inc. | Plasmids for gene editing |
| CA3129871A1 (en) | 2019-03-08 | 2020-09-17 | Zymergen Inc. | Iterative genome editing in microbes |
| US11053515B2 (en) | 2019-03-08 | 2021-07-06 | Zymergen Inc. | Pooled genome editing in microbes |
| EP3942043A2 (en) | 2019-03-19 | 2022-01-26 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| US10982187B2 (en) | 2019-03-26 | 2021-04-20 | Genus Plc | Bos taurus variety ‘HO840003150607238’ and methods of use thereof |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| US10975351B2 (en) | 2019-06-17 | 2021-04-13 | Abs Global, Inc. | Bos taurus variety ‘JE840003146074527’ and methods of use therof |
| CN114729381A (zh) * | 2019-09-05 | 2022-07-08 | 本森希尔股份有限公司 | 修饰基因组的组合物和方法 |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| US20230002761A1 (en) | 2019-11-19 | 2023-01-05 | Benson Hill, Inc. | Anti-bacterial crispr compositions and methods |
| EP4438729A3 (en) | 2019-12-09 | 2025-03-26 | Caribou Biosciences, Inc. | Crispr abasic restricted nucleotides and crispr accuracy via analogs |
| WO2021158918A1 (en) * | 2020-02-05 | 2021-08-12 | Danmarks Tekniske Universitet | Compositions and methods for targeting, editing or modifying human genes |
| WO2021173734A1 (en) * | 2020-02-24 | 2021-09-02 | The Broad Institute, Inc. | Novel type iv and type i crispr-cas systems and methods of use thereof |
| WO2021204877A2 (en) | 2020-04-08 | 2021-10-14 | Astrazeneca Ab | Compositions and methods for improved site-specific modification |
| BR112022022603A2 (pt) | 2020-05-08 | 2023-01-17 | Broad Inst Inc | Métodos e composições para edição simultânea de ambas as fitas de sequência alvo de nucleotídeos de fita dupla |
| WO2021231606A2 (en) * | 2020-05-12 | 2021-11-18 | University Of Massachusetts | Modified guide rnas for crispr genome editing |
| WO2022086846A2 (en) * | 2020-10-19 | 2022-04-28 | Caribou Biosciences, Inc. | Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same |
| CN112301162B (zh) * | 2020-10-22 | 2023-09-22 | 清华-伯克利深圳学院筹备办公室 | 同时检测dna病毒和rna病毒的病毒核酸检测方法 |
| EP4298212A4 (en) * | 2021-02-25 | 2026-04-15 | Celyntra Therapeutics Sa | Compositions and methods for targeting, editing, or modifying genes |
| JP2024513087A (ja) | 2021-04-07 | 2024-03-21 | アストラゼネカ・アクチエボラーグ | 部位特異的改変のための組成物及び方法 |
| GB2628238A (en) * | 2021-09-22 | 2024-09-18 | Verve Therapeutics Inc | Gene editing of PCSK9 or ANGPTL3 and compositions and methods of using same for treatment of disease |
| EP4408996A2 (en) | 2021-09-30 | 2024-08-07 | Astrazeneca AB | Use of inhibitors to increase efficiency of crispr/cas insertions |
| US20250019739A1 (en) | 2021-10-26 | 2025-01-16 | Caribou Biosciences, Inc. | Exonuclease-coupled real-time endonuclease activity assay |
| KR20240099447A (ko) * | 2021-12-07 | 2024-06-28 | 카리부 바이오사이언시스 인코포레이티드 | Crispr 엔도뉴클레아제 절단 생성물을 포획하는 방법 |
| WO2023185697A2 (en) * | 2022-03-29 | 2023-10-05 | Accuredit Therapeutics (Suzhou) Co., Ltd. | Compositions and methods for treatment of transthyretin amyloidosis |
| EP4508211A2 (en) * | 2022-04-13 | 2025-02-19 | Caribou Biosciences, Inc. | Therapeutic applications of crispr type v systems |
| WO2023224327A1 (ko) * | 2022-05-20 | 2023-11-23 | 한국생명공학연구원 | 오토라이신을 활용한 미세조류의 유전자 교정 효율을 증대시키기 위한 시스템 및 방법 |
| US20260035424A1 (en) | 2022-05-26 | 2026-02-05 | Caribou Biosciences, Inc. | Cytokine-receptor fusions for immune cell stimulation |
| EP4511057A1 (en) | 2022-06-06 | 2025-02-26 | Caribou Biosciences, Inc. | Treatment of autoimmune diseases with engineered immune cells |
| EP4578945A4 (en) | 2022-08-26 | 2025-12-17 | Guangzhou Reforgene Medicine Co Ltd | CRISPR-CAS13 SYSTEM AND ITS USE |
| KR20250075567A (ko) | 2022-09-30 | 2025-05-28 | 카리부 바이오사이언시스 인코포레이티드 | 항-ror1 키메라 항원 수용체 (car), car-nk 세포 및 관련 방법 |
| EP4584283A1 (en) | 2022-11-14 | 2025-07-16 | Caribou Biosciences, Inc. | Anti-cll-1 chimeric antigen receptors, engineered cells and related methods |
| EP4414452A1 (en) * | 2023-02-13 | 2024-08-14 | Universidad de Granada | Dual-guide rna composition for executing a single-guide rna crispr-associated system |
| EP4689155A1 (en) | 2023-03-29 | 2026-02-11 | Astrazeneca AB | Use of inhibitors to increase efficiency of crispr/cas insertions |
| US20260014254A1 (en) | 2023-05-01 | 2026-01-15 | Caribou Bioscience, Inc. | Treatment of autoimmune diseases with bcma-targeting engineered immune cells |
| IL324634A (en) | 2023-05-15 | 2026-01-01 | Nchroma Bio Inc | Compositions and methods for epigenetic regulation of hbv gene expression |
| WO2025006880A1 (en) | 2023-06-29 | 2025-01-02 | Caribou Biosciences, Inc. | Diagnostic and therapeutic methods for use with ror1 antagonists |
| WO2025024676A1 (en) | 2023-07-26 | 2025-01-30 | Caribou Biosciences, Inc. | In vitro validation methods for cd19-targeting cell therapies |
| WO2025026439A1 (zh) | 2023-08-02 | 2025-02-06 | 广州瑞风生物科技有限公司 | 基因编辑系统及其应用 |
| CN119614679A (zh) * | 2023-09-14 | 2025-03-14 | 厦门大学 | 一款通用型核酸检测平台 |
| WO2025064930A1 (en) * | 2023-09-20 | 2025-03-27 | Emory University | Nucleic acid hairpin based triggered hydrogels and uses thereof |
| WO2025117745A1 (en) | 2023-12-01 | 2025-06-05 | Caribou Biosciences, Inc. | Methods and compositions for improving precision of endonuclease-mediated genome editing |
| WO2025193609A1 (en) | 2024-03-11 | 2025-09-18 | Caribou Biosciences, Inc. | Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells |
| WO2025193386A1 (en) | 2024-03-13 | 2025-09-18 | Caribou Biosciences, Inc. | Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells |
| WO2026024468A1 (en) | 2024-07-26 | 2026-01-29 | Caribou Biosciences, Inc. | Modular linked chimeric antigen receptors |
| WO2026050087A1 (en) | 2024-08-27 | 2026-03-05 | Caribou Biosciences, Inc. | Real-time crispr endonuclease activity assay |
| US20260085302A1 (en) | 2024-09-20 | 2026-03-26 | Confluence Genetics, Llc | Compositions and methods for controlling plant pests |
| WO2026062583A2 (en) | 2024-09-20 | 2026-03-26 | Confluence Genetics, Llc | Compositions and methods for modifying genomes |
| WO2026083309A1 (en) | 2024-10-17 | 2026-04-23 | Astrazeneca Ab | Use of inhibitors or modulators of artemis in gene editing |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
| US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
| US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| AU7979491A (en) | 1990-05-03 | 1991-11-27 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
| US7256322B2 (en) | 1999-10-01 | 2007-08-14 | Pioneer Hi-Bred International, Inc. | Wuschel (WUS) Gene Homologs |
| WO2005075655A2 (en) | 2004-02-02 | 2005-08-18 | Pioneer Hi-Bred International, Inc. | Ap2 domain transcription factor odp2 (ovule development protein 2) and methods of use |
| PT2126130E (pt) * | 2007-03-02 | 2015-08-03 | Dupont Nutrition Biosci Aps | Culturas com resistência melhorada a fagos |
| EA024121B9 (ru) | 2010-05-10 | 2017-01-30 | Дзе Реджентс Ов Дзе Юниверсити Ов Калифорния | Композиции эндорибонуклеаз и способы их использования |
| GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
| WO2013141680A1 (en) | 2012-03-20 | 2013-09-26 | Vilnius University | RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX |
| US9637739B2 (en) | 2012-03-20 | 2017-05-02 | Vilnius University | RNA-directed DNA cleavage by the Cas9-crRNA complex |
| LT3401400T (lt) * | 2012-05-25 | 2019-06-10 | The Regents Of The University Of California | Būdai ir kompozicijos, skirtos rnr molekulės nukreipiamai tikslinės dnr modifikacijai ir rnr molekulės nukreipiamam transkripcijos moduliavimui |
| JP2015527889A (ja) | 2012-07-25 | 2015-09-24 | ザ ブロード インスティテュート， インコーポレイテッド | 誘導可能なｄｎａ結合タンパク質およびゲノム撹乱ツール、ならびにそれらの適用 |
| ES2576126T3 (es) | 2012-12-12 | 2016-07-05 | The Broad Institute, Inc. | Modificación por tecnología genética y optimización de sistemas, métodos y composiciones enzimáticas mejorados para la manipulación de secuencias |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| EP2896697B1 (en) | 2012-12-12 | 2015-09-02 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| JP2016504026A (ja) | 2012-12-12 | 2016-02-12 | ザ・ブロード・インスティテュート・インコーポレイテッド | 配列操作のための系、方法および最適化ガイド組成物のエンジニアリング |
| EP2931898B1 (en) | 2012-12-12 | 2016-03-09 | The Broad Institute, Inc. | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| IL239317B (en) | 2012-12-12 | 2022-07-01 | Broad Inst Inc | Providing, engineering and optimizing systems, methods and compositions for sequence manipulation and therapeutic applications |
| CN114634950A (zh) | 2012-12-12 | 2022-06-17 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
| SG11201507378UA (en) | 2013-03-14 | 2015-10-29 | Caribou Biosciences Inc | Compositions and methods of nucleic acid-targeting nucleic acids |
| US10378027B2 (en) * | 2013-03-15 | 2019-08-13 | The General Hospital Corporation | RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci |
| WO2014204724A1 (en) * | 2013-06-17 | 2014-12-24 | The Broad Institute Inc. | Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation |
| CA3221516A1 (en) * | 2013-08-22 | 2015-02-26 | E. I. Du Pont De Nemours And Company | Plant genome modification using guide rna/cas endonuclease systems and methods of use |
| EP3835419A1 (en) * | 2013-12-12 | 2021-06-16 | The Regents of The University of California | Methods and compositions for modifying a single stranded target nucleic acid |
| SI3250691T1 (sl) | 2015-01-28 | 2023-10-30 | Caribou Biosciences, Inc. | Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo |
-
2016
- 2016-01-27 SI SI201631744T patent/SI3250691T1/sl unknown
- 2016-01-27 RS RS20230746A patent/RS64527B1/sr unknown
- 2016-01-27 HU HUE16704978A patent/HUE063813T2/hu unknown
- 2016-01-27 KR KR1020197001414A patent/KR102319192B1/ko active Active
- 2016-01-27 FI FIEP16704978.2T patent/FI3250691T3/fi active
- 2016-01-27 PL PL16704978.2T patent/PL3250691T3/pl unknown
- 2016-01-27 KR KR1020227040706A patent/KR20220159498A/ko not_active Ceased
- 2016-01-27 AU AU2016211517A patent/AU2016211517B2/en active Active
- 2016-01-27 CA CA2975166A patent/CA2975166C/en active Active
- 2016-01-27 IL IL288263A patent/IL288263B/en unknown
- 2016-01-27 SG SG10201804715WA patent/SG10201804715WA/en unknown
- 2016-01-27 KR KR1020177023452A patent/KR20170126875A/ko not_active Ceased
- 2016-01-27 RU RU2017130143A patent/RU2713328C2/ru active
- 2016-01-27 SG SG11201705788TA patent/SG11201705788TA/en unknown
- 2016-01-27 PT PT167049782T patent/PT3250691T/pt unknown
- 2016-01-27 SG SG10201906513WA patent/SG10201906513WA/en unknown
- 2016-01-27 GB GB1712504.8A patent/GB2550745A/en not_active Withdrawn
- 2016-01-27 WO PCT/US2016/015145 patent/WO2016123230A1/en not_active Ceased
- 2016-01-27 SM SM20230341T patent/SMT202300341T1/it unknown
- 2016-01-27 NZ NZ733702A patent/NZ733702A/en unknown
- 2016-01-27 JP JP2017539643A patent/JP6835726B2/ja active Active
- 2016-01-27 CA CA3060508A patent/CA3060508C/en active Active
- 2016-01-27 EP EP23176464.8A patent/EP4257690A3/en active Pending
- 2016-01-27 CN CN202010419105.6A patent/CN111518811A/zh active Pending
- 2016-01-27 KR KR1020197028425A patent/KR20190112855A/ko not_active Ceased
- 2016-01-27 BR BR112017016080-3A patent/BR112017016080B1/pt active IP Right Grant
- 2016-01-27 HR HRP20231022TT patent/HRP20231022T1/hr unknown
- 2016-01-27 MX MX2017009506A patent/MX2017009506A/es unknown
- 2016-01-27 CN CN201680007759.XA patent/CN107810270A/zh active Pending
- 2016-01-27 US US15/008,054 patent/US9650617B2/en active Active
- 2016-01-27 ES ES16704978T patent/ES2955957T3/es active Active
- 2016-01-27 DK DK16704978.2T patent/DK3250691T5/da active
- 2016-01-27 LT LTEPPCT/US2016/015145T patent/LT3250691T/lt unknown
- 2016-01-27 EP EP16704978.2A patent/EP3250691B9/en active Active
- 2016-08-16 US US15/238,464 patent/US9580701B2/en active Active
-
2017
- 2017-01-18 US US15/408,920 patent/US9688972B2/en active Active
- 2017-04-21 US US15/493,744 patent/US9771601B2/en active Active
- 2017-07-20 MX MX2024015281A patent/MX2024015281A/es unknown
- 2017-07-23 IL IL253608A patent/IL253608B/en active IP Right Grant
- 2017-07-31 ZA ZA2017/05174A patent/ZA201705174B/en unknown
- 2017-08-17 US US15/679,555 patent/US9868962B2/en active Active
- 2017-12-18 US US15/845,524 patent/US10519468B2/en active Active
-
2018
- 2018-06-13 ZA ZA2018/03945A patent/ZA201803945B/en unknown
- 2018-10-02 IL IL262042A patent/IL262042B/en active IP Right Grant
-
2019
- 2019-05-29 JP JP2019099850A patent/JP7038079B2/ja active Active
- 2019-10-31 US US16/670,832 patent/US11236364B2/en active Active
-
2020
- 2020-03-08 IL IL273147A patent/IL273147B/en unknown
- 2020-07-28 US US16/941,130 patent/US10988781B2/en active Active
-
2021
- 2021-03-22 US US17/208,146 patent/US11459588B2/en active Active
- 2021-05-07 AU AU2021202913A patent/AU2021202913B2/en active Active
-
2022
- 2022-08-15 US US17/888,027 patent/US20230193324A1/en active Pending
-
2023
- 2023-04-04 AU AU2023202056A patent/AU2023202056B2/en active Active
-
2025
- 2025-01-10 US US19/016,766 patent/US20250376700A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2023241391B2 (en) | Novel crispr enzymes and systems | |
| JP2018503386A5 (enExample) | ||
| US20240132877A1 (en) | Genome editing systems comprising repair-modulating enzyme molecules and methods of their use | |
| US20230026726A1 (en) | Crispr/cas-related methods and compositions for treating sickle cell disease | |
| AU2017252023B2 (en) | Materials and methods for treatment of hemoglobinopathies | |
| CN112585268B (zh) | 通过插入供体多核苷酸用于基因组编辑的组合物和方法 | |
| AU2022287660B2 (en) | Rapamycin resistant cells | |
| CN110662838B (zh) | 用于基因编辑的组合物和方法 | |
| US10526590B2 (en) | Compounds and methods for CRISPR/Cas-based genome editing by homologous recombination | |
| US20190048337A1 (en) | Crispr/Cas-Related Methods and Compositions for Treating Duchenne Muscular Dystrophy and Becker | |
| CN110914289A (zh) | 用于工程化细胞的材料和方法及其在免疫肿瘤学中的用途 | |
| CN112424348A (zh) | 新颖的rna-可编程的内切核酸酶系统及其用途 | |
| WO2015148860A1 (en) | Crispr/cas-related methods and compositions for treating beta-thalassemia | |
| IL288263B (en) | CRISPR DNA/RNA hybrid polynucleotides and methods of using them | |
| CN119095972B (zh) | 基因组编辑的组合物和方法 | |
| US20210147841A1 (en) | Compositions and methods for modifying regulatory t cells | |
| CA3127684A1 (en) | Stabilized crispr complexes | |
| CA3200019A1 (en) | Compositions comprising an rna guide targeting pdcd1 and uses thereof | |
| US20250332287A1 (en) | Identification of tissue-specific extragenic safe harbors for gene therapy approaches | |
| Misic | Regulation of mtDNA gene expression and the role of respiratory chain supercomplexes in mammalian mitochondria | |
| TW202440938A (zh) | 用於抑制微管解聚蛋白2(stmn2)轉錄物中異常剪接的基因編輯方法 | |
| Cheruiyot | Nonsense Mediated RNA Decay Promotes Survival of Cells with Defective Splicing | |
| Pérez-Rodríguez | Elucidating A Novel Mechanism Of Dna Silencing Caused By Envelope Stress In Escherichia Coli | |
| Polosa et al. | Mechanism and Regulation of Mitochondrial Transcription in Animal Cells | |
| HK40039896A (en) | Nuclease systems for genetic engineering |